JNJ Q3: Innovative Medicine Strength Masks MedTech Weakness; 2027 Headwinds Loom

What happened

Johnson & Johnson reported Q3 2026 revenue of $25.4 billion, with Innovative Medicine growing 7.9% operationally while MedTech lagged at 2.5% operational growth. Management raised full-year 2026 guidance and adjusted EPS, reflecting confidence in ongoing execution. TREMFYA generated $2.4 billion in quarterly sales, helping offset the steep decline from STELARA biosimilar competition, and positive Phase 3 FUZION data further bolster its clinical positioning. However, MedTech remains a concern, with weakness in Surgery, Abiomed, and international markets only partially offset by Shockwave's 17.2% growth. The report highlights that 2027 could test earnings as further immunology biosimilar erosion (e.g., SIMPONI) and lingering talc litigation risk persist.

Implication

Investors should view the Q3 results as confirming that Innovative Medicine can offset STELARA erosion in the near term, but the MedTech segment remains a drag that may require further restructuring or portfolio action to improve. The raised guidance suggests management's base case is tracking, yet the 2027 headwind from additional biosimilars and unresolved talc litigation means the margin of safety is still thin at current valuation near $228. The thesis hinges on whether immunology stabilization can hold through the CVS formulary switch and beyond, and whether MedTech margins can recover as Surgery restructuring completes by end-2026. We maintain our WAIT rating with attractive entry near $200 and trim above $245, as the risk/reward remains balanced until either a legal catalyst or a clearer MedTech turnaround emerges.

Thesis delta

The Q3 report provides evidence that Innovative Medicine's growth is sufficient to offset STELARA erosion in 2026, reducing the probability of a bear-case steep decline. However, the MedTech segment's persistent underperformance and the looming 2027 biosimilar wave keep the thesis in a wait-and-see mode. The overall thesis shifts from cautious to guarded optimism, but we require confirmation of MedTech improvement or talc resolution before upgrading.